Efficacy of lurasidone in first-episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel

Introduction: For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the l...

Descripción completa

Detalles Bibliográficos
Autores: Bernardo, Miquel, Díaz Marsa, Marina, González-Pinto, Ana, Martín Carrasco, Manuel, Pérez Solà, Víctor, Saiz, Pilar A., Vieta, Eduard, Torrens, Marta, Arango, Celso, Crespo-Facorro, Benedicto
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/72765
Acceso en línea:https://hdl.handle.net/10230/72765
http://dx.doi.org/10.1007/s40120-024-00700-y
Access Level:acceso abierto
Palabra clave:Antipsychotic
First-episode psychosis
Lurasidone
Schizophrenia
Tolerability
Treatment
id ES_3d2c860b7af7ef77d2fe4538bdb49821
oai_identifier_str oai:repositori.upf.edu:10230/72765
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy of lurasidone in first-episode psychosis: patient phenotypes, dosage, and recommendations from an expert panelBernardo, MiquelDíaz Marsa, MarinaGonzález-Pinto, AnaMartín Carrasco, ManuelPérez Solà, VíctorSaiz, Pilar A.Vieta, EduardTorrens, MartaArango, CelsoCrespo-Facorro, BenedictoAntipsychoticFirst-episode psychosisLurasidoneSchizophreniaTolerabilityTreatmentIntroduction: For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13-17 years). The efficacy and tolerability of lurasidone have been demonstrated in both antipsychotic-naïve and previously treated patients. Areas Covered: This paper provides a review and commentary regarding the use of lurasidone in patients with FEP. Case studies based on the author's clinical experiences with lurasidone in real-world practice are provided. Expert Opinion: In our experience, lurasidone has shown efficacy in FEP in different patient profiles, including those with psychoses associated with substance use disorders. Lurasidone provides clinically relevant benefits, especially in patients with affective symptomatology, and has a good tolerability profile.Springer2026202620252026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/10230/72765http://dx.doi.org/10.1007/s40120-024-00700-yreponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésNeurology and Therapy. 2025;14(1):85-98© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.http://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/727652026-06-12T07:21:37Z
dc.title.none.fl_str_mv Efficacy of lurasidone in first-episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
title Efficacy of lurasidone in first-episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
spellingShingle Efficacy of lurasidone in first-episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
Bernardo, Miquel
Antipsychotic
First-episode psychosis
Lurasidone
Schizophrenia
Tolerability
Treatment
title_short Efficacy of lurasidone in first-episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
title_full Efficacy of lurasidone in first-episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
title_fullStr Efficacy of lurasidone in first-episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
title_full_unstemmed Efficacy of lurasidone in first-episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
title_sort Efficacy of lurasidone in first-episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
dc.creator.none.fl_str_mv Bernardo, Miquel
Díaz Marsa, Marina
González-Pinto, Ana
Martín Carrasco, Manuel
Pérez Solà, Víctor
Saiz, Pilar A.
Vieta, Eduard
Torrens, Marta
Arango, Celso
Crespo-Facorro, Benedicto
author Bernardo, Miquel
author_facet Bernardo, Miquel
Díaz Marsa, Marina
González-Pinto, Ana
Martín Carrasco, Manuel
Pérez Solà, Víctor
Saiz, Pilar A.
Vieta, Eduard
Torrens, Marta
Arango, Celso
Crespo-Facorro, Benedicto
author_role author
author2 Díaz Marsa, Marina
González-Pinto, Ana
Martín Carrasco, Manuel
Pérez Solà, Víctor
Saiz, Pilar A.
Vieta, Eduard
Torrens, Marta
Arango, Celso
Crespo-Facorro, Benedicto
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Antipsychotic
First-episode psychosis
Lurasidone
Schizophrenia
Tolerability
Treatment
topic Antipsychotic
First-episode psychosis
Lurasidone
Schizophrenia
Tolerability
Treatment
description Introduction: For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13-17 years). The efficacy and tolerability of lurasidone have been demonstrated in both antipsychotic-naïve and previously treated patients. Areas Covered: This paper provides a review and commentary regarding the use of lurasidone in patients with FEP. Case studies based on the author's clinical experiences with lurasidone in real-world practice are provided. Expert Opinion: In our experience, lurasidone has shown efficacy in FEP in different patient profiles, including those with psychoses associated with substance use disorders. Lurasidone provides clinically relevant benefits, especially in patients with affective symptomatology, and has a good tolerability profile.
publishDate 2025
dc.date.none.fl_str_mv 2025
2026
2026
2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/10230/72765
http://dx.doi.org/10.1007/s40120-024-00700-y
url https://hdl.handle.net/10230/72765
http://dx.doi.org/10.1007/s40120-024-00700-y
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Neurology and Therapy. 2025;14(1):85-98
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406422933962752
score 15,811543

Similares en LA Referencia